Prognostic importance of tobacco use in men receiving definitive prostate brachytherapy

• Published in: Brachytherapy Vol. 11; no. 6; pp. 446 - 451
• Main Authors: Taira, Al V, Merrick, Gregory S, Galbreath, Robert W, Butler, Wayne M, Bennett, Abbey, Adamovich, Edward, Lief, Jonathan H, Wallner, Kent E
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2012
• Subjects: Aged; Biochemical progression-free survival; Brachytherapy - mortality; Comorbidity; Hematology, Oncology and Palliative Medicine; Humans; Incidence; Male; Middle Aged; Neoplasm Recurrence, Local - mortality; Neoplasm Recurrence, Local - prevention & control; Overall survival; Prognosis; Prostate cancer; Prostate cancer-specific survival; Prostatic Neoplasms - mortality; Prostatic Neoplasms - radiotherapy; Radiology; Risk Factors; Smoking; Smoking - mortality; Survival Analysis; Survival Rate; Treatment Outcome; United States - epidemiology; United States; Biochemical progression-free survival; Overall survival; Prostate cancer-specific survival; Prostate cancer; Smoking
• DOI: 10.1016/j.brachy.2012.02.001
• ISSN: 1538-4721

Abstract Purpose Several prominent publications have identified an overall association between tobacco use and an increased risk of disease recurrence and disease-specific mortality in prostate cancer patients. The authors explored whether tobacco use adversely impacts treatment outcomes in men treated with permanent interstitial brachytherapy. Methods and Materials From April 1995 to August 2008, 2057 patients underwent brachytherapy by a single brachytherapist. Median follow-up was 7.5 years. The role of tobacco use as a prognostic factor for biochemical progression-free survival, cause-specific survival, and overall survival was investigated. Differences in survival between smokers and nonsmokers were compared using Kaplan–Meier curves and log-rank tests. Results Current smokers presented with a lower body mass index ( p < 0.001), smaller prostate size ( p = 0.003), younger age ( p < 0.001), higher prostate-specific antigen level ( p = 0.002), a trend toward higher percentage biopsy core involvement ( p = 0.08), higher incidence of perineural invasion ( p = 0.015), and higher risk disease ( p < 0.001) than former or nonsmokers. There was no difference in biochemical progression-free survival ( p = 0.30) or cause-specific survival ( p = 0.72) at 10 years for smokers compared with nonsmokers. On univariate and multivariate analysis, tobacco use was an adverse risk factor for overall survival ( p < 0.001). There was no association between smoking and any prostate cancer-specific outcome. Conclusions Smokers treated with brachytherapy have excellent outcomes and are at no higher risk of treatment failure than men who are nonsmokers.